Trial over Pfizer's Zoloft gets underway; Aurobindo selling Australian unit;

@FiercePharma: ICYMI from FiercePharmaManufacturing: Chinese drugmaker to build $60M API plant. News | Follow @FiercePharma

@EricPFierce: Supply chain slip results in expired Pfizer birth control pills being sold in Canada. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Eisai to shed 450 jobs as it pares down U.S. workforce by one-fourth. News | Follow @CarlyHFierce

> Aurobindo is selling its Australian subsidiary to Eris Pharma for an undisclosed sum to focus on sales in the U.S., emerging markets and Europe. Report

> A federal trial that will test whether a jury believes that pregnant women taking Pfizer's ($PFE) Zoloft risked having babies with heart defects has gotten underway in St. Louis. Story

> Walgreens Boots Alliance Inc. ($WBA) will close 200 Walgreens drugstores in the U.S. to cut another $500 million in costs. Story

> Biocon has gotten approval in Mexico to sell its Glargine diabetes drug. Story

Medical Device News

@FierceMedDev: Biocartis joins forces with Microbiome for quick sepsis test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA finalizes accelerated approval pathway for critical devices, aims to get med tech to market faster. Article | Follow @VarunSaxena2

@EmilyWFierce: Diagnosing Winnie the Pooh characters from the DSM. Just your typical Friday. | Follow @EmilyWFierce

> Pryor Medical gears up for rollout of military-inspired catheter. More

> Report: Demise of NeuroControl a cautionary tale of 'Orphan Markets' for devicemakers. Story

> Startup receives $20M in funding to test its leadless pacemaker. Article

Biotech News

@FierceBiotech: EuroBiotech: Woodford: It's a bubble, Pfizer-backed IO player plans IPO, UniQure cashes in on Bristol deal. More | Follow @FierceBiotech

@JohnCFierce: Eisai cuts follow GlaxoSmithKline, Amgen, Merck, Sanofi, Pfizer, AstraZeneca, Shire, etc... Over 4 months. More | Follow @JohnCFierce

@DamianFierce: ICYMI: The thrilling conclusion to #FierceMadness and why I've had "One Shining Moment" stuck in my head all day. Winner | Follow @DamianFierce

> Safety scare with AstraZeneca's diabetes drug could shake up the DPP-4 field. News

> Carbylan pulls off a $65M IPO on its second go-round. Article

> Shire's billion-dollar eye drug gets in line for a speedy FDA review. Story

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

Pfizer is using a "build-buy-partner" strategy to bring outside gene therapy candidates into its growing manufacturing space in North Carolina.